No authentic data on spurious drugs: CBI Chief

Image
Press Trust of India Ghaziabad
Last Updated : Oct 08 2013 | 8:26 PM IST
Not even one per cent of the accused have been arrested in cases of spurious medicine trafficking in 20011-12 in the country which lacks authentic data on the extent of the problem, CBI Director Ranjit Sinha said today.
Expressing concern over poor detection of spurious drug network in the country, Sinha said, "According to the statistics of the year 2011-12 (upto March 2012) of Ministry of Health and Family Welfare, out of 48,082 drugs tested across the country, 133 turned out to be fake, which translates to roughly 0.27 per cent."
He said prosecution was launched only in 0.43 per cent of these 133 cases and only 0.23 per cent of accused who were found involved in the manufacture of these fake drugs were arrested.
Speaking at the three-day training on 'Investigation of Trafficking of Spurious Medical Products' in collaboration with Interpol, Sinha said failure to prosecute an accused could be due to several factors including lack of expertise on the part the investigating officers to gather evidence to implicate the accused.
"...Counterfeiting cases that are detected and investigated are not prosecuted, perhaps due to certain weaknesses in investigation. Needless to say that the investigating capability of officers is required to be beefed up," Sinha said.
The CBI Chief said low detection rate could be due to lack of an efficient intelligence collection apparatus or awareness among the stake holders.
"It has been difficult to assess the extent of the problem of counterfeit medicines in many settings because of the lack of resources or skills to detect counterfeit medicines, the absence or weak medicines regulatory systems, the different definitions of counterfeit medicines in different countries worldwide, as well as the variations in the distribution systems," he said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 08 2013 | 8:26 PM IST

Next Story